Diagnostic innovation moved on two fronts, with one regulatory milestone and one translational imaging advance. The FDA granted Zepto Life Technologies breakthrough device designation for its FungiFlex Mold Panel, a plasma-based cell-free DNA assay intended to detect invasive mold infections and distinguish clinically relevant fungal species from circulating cfDNA. In imaging, Kyushu University researchers reported a rapid, minimally invasive X-ray technique to quantify heart valve regurgitation severity in patients with repaired congenital defects, targeting pulmonary valve regurgitation as a long-term complication after Tetralogy of Fallot. Together, the updates reflect ongoing pressure to shorten time-to-diagnosis and improve measurement precision—particularly for conditions where earlier decision-making can change care trajectories.